Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Azacitidine Plus Luspatercept Versus Azacitidine Monotherapy in Higher-risk Myelodysplastic Neoplasms: a Randomized Prospective Study

NCT06927232 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT06927232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06927232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Azacitidine Plus Luspatercept Versus Azacitidine Monotherapy in Higher-risk Myelodysplastic Neoplasms: a Randomized Prospective Study
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
January 31, 2027
Enrollment
86 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

higher-risk myelodysplastic syndrome